Health
Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder
Indivior PLC (Nasdaq/LSE: INDV) today announced results from a new retrospective real-world study published in Drug and Alcohol Dependence Reports, which examined demographic and clinical factors associated with ED visits among adults diagnosed with opioid use disorder (OUD) over a six-month follow-up period.
About this update from Indivior Pharmaceuticals, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Extended-release buprenorphine (BUP-XR) had lower rates of hospitalizations, emergency department (ED) visits, and outpatient physician office visits compared to those receiving daily oral buprenorphine or no medications for opioid use disorder (MOUD)","length":269,"tagName":"p"}]},{"val":[{"type":"text","content":"The study indicates BUP-XR may be an important tool in reducing ED visits, improving healthcare resource utilization and patient outcomes","length":142,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":411,"olType":false},{"type":"text","content":"RICHMOND, Va., July 23, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced results from a new retrospective real-world study published in Drug and Alcohol Dependence Reports, which examined demographic and clinical factors associated with ED visits among adults diagnosed with opioid use disorder (OUD) over a six-month follow-up period.","length":365,"tagName":"p"},{"type":"image","alt":"Indivior (PRNewsfoto/Indivior)","displaySize":"","headline":null,"caption":"Indivior (PRNewsfoto/Indivior)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":130,"url":"https://media.zenfs.com/en/prnewswire.com/e9a6eb17aaf44dddfab6f7d13d2315b7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.uJSnzZQQuSzYp3kZpAAsQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIyOTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/e9a6eb17aaf44dddfab6f7d13d2315b7","width":400,"height":130}},"href":"https://mma.prnewswire.com/media/1814851/Indivior_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The study found that patients treated with BUP-XR, in the form of the once-monthly long-acting injectable formulation of buprenorphine, had 57% lower odds of all-cause ED visits compared to those who received no MOUD. Additionally, patients treated with BUP-XR experienced significantly fewer hospitalizations and lower inpatient costs compared to those receiving daily oral buprenorphine or no MOUD.","length":474,"tagName":"p"},{"type":"text","content":""Opioid overdose-related ED visits are a critical concern in the ongoing opioid epidemic,&quo...